Nestea introduces green tea with higher antioxidant concentration
ATLANTA Iced Tea brand Nestea announced today the launch of its new Green Tea Citrus and Diet Green Tea Citrus products with 50 percent more antioxidants than before, as well as a brand new look.
The new varieties combine all-natural fruit flavors and the natural goodness of tea, largely in response to consumer health awareness. Both products now contain 50 percent more natural tea antioxidants, with 96 milligrams of flavonoid antioxidants per eight fluid ounce serving.
“As summer approaches, it is the perfect time to introduce products for consumers who want to quickly revitalize their day,” said Penny McIntyre, senior vice president and general manager of coffee and tea for Coca-Cola North America. “Nestea offers delicious, simple blends of tea and natural fruit flavors. Our new Green Tea Citrus products with even more antioxidants are great additions to our line of refreshing teas.”
The new packaging features dynamic graphics that call attention to the antioxidant content and all-natural fruit flavors. Nestea’s Iced Tea with Lemon and Diet Iced Tea with Lemon flavors come in 20 ounce and half-liter plastic bottle 12-packs. The Iced Tea with Lemon also comes in aluminum cans (regular and diet) and 2-liter plastic bottles (regular).
Study: pharmacist monitoring can help hypertension
SEATTLE An experiment by the Seattle-based Group Health Cooperative has found that Web-based monitoring by pharmacists can help control hypertension.
It found that 56 percent of patients assigned home blood pressure monitoring, Web site training and Web-based pharmacist care experienced increases in control of blood pressure. Those who received the blood pressure monitoring and Web site training only did not experience a significant increase.
The study involved 778 patients ages 25 to 75 in three groups with uncontrolled essential hypertension and Internet access between June 2005 and December 2007.
Results of the study appeared in Wednesday’s issue of the Journal of the American Medical Association.
Genzyme, Isis complete license agreement for cholesterol drug
CAMBRIDGE, Mass. Genzyme and Isis Pharmaceuticals announced Tuesday that they had finished a license and collaboration agreement for mipomersen, a drug candidate designed for patients with high cholesterol.
Under the agreement, Genzyme will pay Isis $175 million in licensing fees. Isis will contribute up to $175 million for development. After that, the two companies will share development costs. Isis may also receive up to $1.5 billion in commercial, development and regulatory milestone payments. Genzyme will have preferred access to future drugs that Isis develops for rare diseases and diseases affecting the central nervous system.
The companies will share profits for the drug, with Genzyme receiving 70 percent and Isis receiving 30 percent. They will split profits equally once revenues on mipomersen reach $2 billion. Genzyme will also be responsible for funding sales and marketing until revenues can cover them.
“Mipomersen is an innovative treatment that has the potential to change the standard of care for severely ill patients whose needs cannot be addressed by current cholesterol-lowering therapies,” said Henri A. Termeer, Genzyme’s chairman and chief executive officer.